{"entity":{"id":"senti-202","kind":"drug","name":"SENTI-202","aka":[],"tldr":"SENTI-202 is an experimental off-the-shelf logic-gated CAR-NK cell therapy from Senti Biosciences, in phase 1 trials for acute myeloid leukaemia, myelodysplastic syndromes and CD33- or FLT3-expressing haematological malignancies.","summary":"SENTI-202 is an off-the-shelf logic-gated CAR-NK cell therapy (donor NK cells) from Senti Biosciences. NK cells from healthy adult donors carry an activating CAR that recognises CD33 and/or FLT3 (OR gate), an inhibitory CAR that recognises healthy cells to protect them (NOT gate, named EMCN), and calibrated-release IL-15 to increase persistence and activity. Its furthest stage is phase 1, for acute myeloid leukaemia, myelodysplastic syndromes and CD33- or FLT3-expressing haematological malignancies. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06325748, active not recruiting per registry; FDA Orphan Drug Designation for relapsed/refractory haematologic malignancies including AML (company page). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Senti Biosciences: sentibio.com","url":"https://www.sentibio.com/research-pipeline/senti-202/"},{"label":"Senti Biosciences: sentibio.com","url":"https://www.sentibio.com/research-pipeline/senti-202/"},{"label":"Senti Biosciences: sentibio.com","url":"https://www.sentibio.com/research-pipeline/pipeline/"},{"label":"ClinicalTrials.gov: trials of SENTI-202","url":"https://clinicaltrials.gov/search?intr=SENTI-202"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","metastatic-cancer"],"sections":[],"technologies":[],"targets":["cd33","flt3"],"drugs":[],"companies":["senti-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06325748"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SENTI-202","modality":"Off-the-shelf logic-gated CAR-NK cell therapy (donor NK cells)","mechanism":"NK cells from healthy adult donors carry an activating CAR that recognises CD33 and/or FLT3 (OR gate), an inhibitory CAR that recognises healthy cells to protect them (NOT gate, named EMCN), and calibrated-release IL-15 to increase persistence and activity.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/senti-202/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/"},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"company":[{"id":"senti-biosciences","kind":"company","name":"Senti Biosciences","route":"/companies/senti-biosciences/"}],"trial":[{"id":"nct06325748","kind":"trial","name":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","route":"/trials/nct06325748/"}]}}